CV Sciences ( (CVSI) ) has released its Q3 earnings. Here is a breakdown of the information CV Sciences presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CV Sciences, Inc. is a consumer wellness company that specializes in hemp extracts and other science-backed, natural ingredients, operating primarily in the nutraceuticals and plant-based foods sector. The company is known for its +PlusCBD™ branded products, which are top-selling in the natural products market.
In the third quarter of 2025, CV Sciences reported a revenue of $3.3 million, a decrease from the previous year’s $3.9 million. Despite the revenue decline, the company achieved a gross margin of 48.5%, showing improvement from the previous year’s 46.0%. The company also launched a new product, Ignite, aimed at enhancing men’s performance, which is part of their strategy to drive organic growth.
The financial results indicate a challenging quarter with an adjusted EBITDA loss of $118,000, compared to a loss of $75,000 in the same quarter of the previous year. The company attributes the decline in sales to out-of-stock issues and restrictive regulations in certain states. However, 39% of the quarter’s net revenue was generated from new products launched since January 2023, highlighting the company’s commitment to innovation and product diversification.
Looking ahead, CV Sciences is focused on enhancing top-line revenue and shareholder value through strategic M&A opportunities and new product development. The company is also navigating regulatory challenges in the hemp industry, with plans to work with Congress to shape a balanced regulatory framework. Management remains committed to building a balanced portfolio aimed at sustainable growth and profitability.